• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Chemical Profile of (R)-Cyclopropyl(phenyl)methanamine (CAS No. 434307-26-3)

(R)-Cyclopropyl(phenyl)methanamine, identified by its Chemical Abstracts Service number CAS No. 434307-26-3, is a chiral amine compound that has garnered significant attention in the field of pharmaceutical chemistry and drug discovery. This compound belongs to the class of secondary amines and features a cyclopropyl group attached to a phenyl ring, which contributes to its unique structural and functional properties. The enantiomeric purity of this compound, specifically the (R)-configuration, makes it a valuable building block for the synthesis of biologically active molecules.

The significance of chiral compounds in pharmaceuticals cannot be overstated. The (R)-configuration of (R)-Cyclopropyl(phenyl)methanamine plays a crucial role in determining the biological activity and pharmacokinetic behavior of the final drug candidates. Recent advancements in asymmetric synthesis have enabled the efficient production of enantiomerically pure compounds like this one, which is essential for developing drugs with improved efficacy and reduced side effects.

In the context of drug discovery, (R)-Cyclopropyl(phenyl)methanamine has been explored as a key intermediate in the synthesis of various pharmacologically relevant molecules. Its structural motif, combining a cyclopropyl group with a phenyl ring, is known to enhance binding affinity and metabolic stability, making it an attractive scaffold for medicinal chemists. For instance, studies have demonstrated its utility in the development of novel central nervous system (CNS) agents, where the cyclopropyl group contributes to blood-brain barrier penetration.

Recent research has highlighted the potential of (R)-Cyclopropyl(phenyl)methanamine in the treatment of neurological disorders. The compound has been investigated for its ability to modulate neurotransmitter systems, particularly serotonin and dopamine pathways, which are implicated in conditions such as depression and schizophrenia. Preclinical studies have shown promising results in animal models, indicating that derivatives of this compound may exhibit therapeutic potential.

The synthesis of complex pharmaceuticals often requires multi-step organic transformations, and (R)-Cyclopropyl(phenyl)methanamine serves as a versatile intermediate in such processes. Advanced synthetic methodologies, including transition-metal-catalyzed cross-coupling reactions and enzymatic resolutions, have been employed to achieve high yields and enantiomeric purity. These techniques not only improve the efficiency of drug synthesis but also reduce environmental impact by minimizing waste generation.

The pharmacological properties of (R)-Cyclopropyl(phenyl)methanamine have been further explored through computational modeling and molecular dynamics simulations. These studies have provided insights into its interactions with biological targets, such as receptors and enzymes, which are critical for understanding its mechanism of action. By integrating experimental data with computational approaches, researchers can optimize the structure-activity relationships (SAR) of drug candidates derived from this compound.

In addition to its applications in CNS disorders, (R)-Cyclopropyl(phenyl)methanamine has shown promise in other therapeutic areas. For example, it has been investigated as a precursor for anti-inflammatory agents, where its structural features contribute to modulating immune responses. The cyclopropyl group is particularly noteworthy for its ability to engage with specific binding pockets on target proteins, leading to enhanced drug potency.

The development of novel synthetic routes for (R)-Cyclopropyl(phenyl)methanamine continues to be an active area of research. Innovations in flow chemistry and continuous manufacturing have enabled scalable production processes that meet the demands of industrial applications. These advancements not only enhance cost-effectiveness but also ensure consistent quality control throughout the synthesis process.

The safety and regulatory aspects of working with (R)-Cyclopropyl(phenyl)methanamine are also critical considerations. While it is not classified as a hazardous material under current regulations, proper handling procedures must be followed to ensure workplace safety. This includes using appropriate personal protective equipment (PPE) and maintaining controlled environments to prevent contamination.

Ethical considerations in pharmaceutical research are paramount, particularly when dealing with chiral compounds that can exhibit different biological activities depending on their configuration. Responsible research practices ensure that all synthetic processes are conducted with minimal environmental impact and that intellectual property rights are respected throughout drug development.

The future prospects for (R)-Cyclopropyl(phenyl)methanamine in pharmaceutical applications appear promising. Ongoing research aims to expand its utility in diverse therapeutic areas by developing novel derivatives with enhanced pharmacological profiles. Collaborative efforts between academia and industry will be essential in translating these findings into clinical reality.

• 56640-53-0(2-Methyl-1-phenyl-butylamine)
• 681509-99-9(Benzenemethanamine, a-(cyclopropylmethyl)-)
• 23459-38-3(1-Cyclopropyl-1-phenylmethanamine)
• 535925-71-4(cyclopropyl(4-methylphenyl)methanamine)
• 140167-41-5(Cyclopropyl(4-propylphenyl)methanamine)
• 321863-61-0((s)-1-cyclopropyl-1-phenylmethanamine)
• 844470-80-0((1S)-Cyclopropylphenylmethylamine Hydrochloride)
• 535925-72-5(Cyclopropyl-(3-methylphenyl)methanamine)
• 1416450-04-8((R)-cyclopropyl(phenyl)methanamine hydrochloride)
• 39959-72-3(cyclopropyl(phenyl)methanamine;hydrochloride)